greeksoup/ stock research

OptimizeRx (OPRX) Q3 FY2026 earnings: revenue $22 million, down 17.1% on the year

OptimizeRx Corp. (OPRX) reported revenue of $22 million for Q3 FY2026, the quarter ended 30 September 2026, down 17.1% on the same quarter a year earlier. Net income was $1 million, up 53.4% on the year, and diluted earnings per share $0.06. The figures are the company's own, from the 10-Q it filed with the SEC on 13 November 2026.

Revenue
$22 million
-17.1% on the year · +5.4% on the quarter
Q4 FY2024Q3 FY2026
Operating margin
12.4%
7.9% a year earlier
Q4 FY2024Q3 FY2026
Net income
$1 million
+53.4% on the year
Q4 FY2024Q3 FY2026
Diluted EPS
$0.06
+50.0% on the year
Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

What management said

Guidance figures: 1 lowered, 1 kept.

  • Revenue fell 17% year over year: Q3 revenue was $21.6 million against $26.1 million a year earlier. Management attributed the decline mainly to reduced spending by a limited number of large customers.
  • Net revenue retention fell to 83%: Net revenue retention was 83% on a rolling twelve-month basis, against 121% a year earlier. Management said a few large accounts optimizing spend drove the dip rather than broad churn.
  • Displaced top-five client returned: A client that was about 10% of 2025 revenue had no revenue in the first three quarters of 2026. Revenue from it began in Q4, but spending has not yet returned to historical levels.
Read the earnings call summary

Income statement (profit and loss)

$ millionQ3 FY2026Q2 FY2026Q3 FY2025On the quarterOn the yearLast 8 quarters
Revenue21.620.526.1+5.4%-17.1%
Cost of revenue5.44.88.6+11.5%-37.2%
Gross profit16.215.717.5+3.6%-7.3%
Gross margin75.2%76.5%67.2%
Research and development2.93.32.7-10.5%+7.6%
Operating income2.7-0.12.1+28.9%
Operating margin12.4%-0.4%7.9%
Interest expense0.21.11.2-84.3%-84.7%
Pre-tax income2.6-1.11.1+139.8%
Income tax1.4-0.40.3+407.8%
Effective tax rate53.4%n/a25.2%
Net income1.2-0.70.8+53.4%
Net margin5.5%-3.4%3.0%
Diluted EPS$0.06-$0.04$0.04+50.0%
$ million except per share.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed.

Cash flow

$ millionQ3 FY2026Q2 FY2026Q3 FY2025On the quarterOn the yearLast 8 quarters
Operating cash flow4.78.63.2-45.0%+47.9%
Capital expenditure0.00.00.0-65.7%+20.0%
Free cash flow4.78.63.2-44.9%+48.0%
Free cash flow margin21.9%41.8%12.2%
Cash from investing-0.0-0.0-0.0
Cash from financing-6.5-4.7-0.3
Depreciation and amortisation1.11.11.10.0%-1.5%
Share-based compensation1.82.22.0-19.2%-8.8%
Diluted shares, weighted19m19m19m+2.3%-1.2%
Shares outstanding at period end19m19m19m+0.4%+1.7%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ millionQ3 FY2026Q2 FY2026Q3 FY2025On the quarterOn the yearLast 8 quarters
Shareholders' equity134131122+2.1%+9.5%
Debt13.419.728.8-32.1%-53.5%
Operating lease liabilities0.20.20.3-24.8%-38.3%
Other liabilities14.713.319.0+10.2%-22.7%
Total liabilities and equity162164170-1.4%-4.8%
Fixed assets0.10.10.1-5.7%-3.4%
Goodwill70.970.970.90.0%0.0%
Intangible assets37.738.75.0-2.7%+651.3%
Cash and equivalents22.324.119.5-7.3%+14.4%
Receivables25.224.832.2+1.5%-21.9%
Other assets5.95.742.6+3.9%-86.0%
Total assets162164170-1.4%-4.8%

Questions

What was OptimizeRx's revenue in Q3 FY2026?

OptimizeRx (OPRX) reported revenue of $22 million for Q3 FY2026, the quarter ended 30 September 2026, down 17.1% on the same quarter a year earlier.

How much did OptimizeRx earn in Q3 FY2026?

Net income for Q3 FY2026 was $1 million, up 53.4% on the year, and diluted earnings per share $0.06.

When did OptimizeRx report Q3 FY2026 results?

OptimizeRx filed its 10-Q for the quarter ended 30 September 2026 with the SEC on 13 November 2026.

Quarterly results, the last 20 quarters

Q4 FY2021 *Q1 FY2022Q2 FY2022Q3 FY2022Q4 FY2022 *Q1 FY2023 †Q2 FY2023 †Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025 †Q2 FY2025 †Q3 FY2025 †Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026
Revenue20.313.714.015.119.713.013.816.328.419.718.821.332.321.929.226.132.219.820.521.6
Cost of revenue7.95.65.05.77.25.66.06.510.57.57.17.910.38.610.68.68.14.94.85.4
Gross profit12.48.19.09.412.57.47.89.817.812.211.713.422.013.318.617.524.114.915.716.2
Gross margin61%59%64%62%63%57%57%60%63%62%62%63%68%61%64%67%75%75%77%75%
R&Dn/an/an/an/an/an/an/an/an/an/an/an/an/a3.33.12.7-9.13.43.32.9
SG&A18.93.43.93.822.414.012.212.9n/an/an/an/an/an/an/an/an/an/an/an/a
Operating income0.6-3.8-3.9-3.8-0.9-7.1-4.8-3.6-10.9-5.0-3.7-8.63.6-2.13.22.18.60.4-0.12.7
Operating margin3%-27%-28%-25%-4%-54%-35%-22%-38%-26%-20%-40%11%-10%11%8%27%2%-0%12%
Interest expensen/an/an/an/an/an/an/an/an/a1.51.51.51.61.31.61.21.21.21.10.2
Pre-tax income0.6-3.8-3.9-3.5-0.3-6.4-4.1-2.9-11.7-6.6-5.1-9.92.2-3.31.71.17.5-0.6-1.12.6
Tax raten/an/an/an/an/an/an/an/an/an/an/an/a104%n/a10%25%33%n/an/a53%
Net income0.6-3.8-3.9-3.5-0.3-6.4-4.2-2.9-4.1-6.9-4.0-9.1-0.1-2.21.50.85.0-0.5-0.71.2
Net margin3%-27%-28%-23%-2%-49%-30%-18%-15%-35%-21%-43%-0%-10%5%3%16%-2%-3%6%
Diluted EPS$0.04-$0.21-$0.21-$0.19-$0.03-$0.37-$0.24-$0.17-$0.25-$0.38-$0.22-$0.50$0.00-$0.12$0.08$0.04$0.26-$0.03-$0.04$0.06
Operating cash flow-1.34.10.33.52.8-0.1-2.41.5-6.32.10.81.80.23.94.63.27.1-0.58.64.7
Capital expenditure0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Free cash flow-1.44.10.33.42.8-0.1-2.41.4-6.32.10.71.80.23.84.63.27.1-0.58.64.7
Buybacksn/an/a0.312.2n/an/a7.50.0n/an/an/an/an/an/an/an/an/an/an/an/a
Shares outstanding18m18m18m18m18m18m18m18m18m18m18m18m18m18m19m19m19m19m19m19m
Filing10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 30 September 2026, filed 13 November 2026: the filing.